David Erritzoe

David Erritzoe is a renowned figure in the field of psychiatry and neuroscience with a rich educational background and extensive research experience.

He graduated from the University of Copenhagen in 2001 and went on to pursue specialized training in molecular brain imaging at Columbia University in 2003-04.

His academic journey continued with a PhD and post-doc focusing on PET and MRI imaging of the brain's 5HT system at Rigshospitalet, Copenhagen.

Since 2009, David has been conducting groundbreaking research at Imperial College London, under the guidance of distinguished professors, in brain imaging related to addiction and depression.

His current research focuses on developing new imaging techniques to study the DA and 5HT systems, investigating various aspects of addiction including alcohol addiction, opioid neurotransmission, and the role of receptors in cocaine, alcohol, and heroin addiction.

David has also been involved in brain imaging and therapy studies involving MDMA and classic psychedelics.

As of 2020, he leads investigations on various topics including reward processing in gambling disorder, psychedelic microdosing, mechanisms of ketamine's therapeutic effects, and clinical trials on DMT in major depression.

In addition to his research, he has held multiple academic positions at Imperial College London and various NHS trusts, including a Clinical Director role at the Centre for Psychedelic Research, and heading a research clinic at CNWL's St Charles Hospital.

David has received grants and awards for his research, published over 65 peer-reviewed scientific papers, and presented at more than 70 international conferences.

His impressive contributions have earned him a high citation count on Google Scholar and recognition in the scientific community with an h-index of 37 and i10-index of 60.